Shire Faces Another Challenge To Patent For Adderall XR

Law360, New York (December 3, 2004, 12:00 AM EST) -- Another generic drug maker has launched a challenge against the patent for Shire Pharmaceuticals Group PLC’s Adderall XR, a blockbuster drug for the treatment of attention deficit and hyperactivity disorders.

Colony Pharmaceuticals Inc. has filed an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration (FDA) for a generic version of Shire's amphetamine Adderall XR, Shide said.

Adderall is indicated as an integral part of a total treatment program, which typically includes other measures) for patients with the syndrome. The patents protecting Adderall...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.